Paper Details

  1. Home
  2. Paper Details

C-Reactive Protein Is a Poor Marker of Baseline Inflammation in Prostate Cancer and Response to Radiotherapy or Androgen Ablation.

Author: HammondsKendall P, JensenGarrett L, JhavarSameer G, NaziriJason, SwansonGregory

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

C-reactive protein (CRP) levels were evaluated in patients with prostate cancer at various time points during treatment with androgen ablation and radiotherapy. CRP levels were not significantly associated with PSA, lymphocytes, or treatment response. This suggests that CRP is not a reliable marker for inflammation caused by prostate cancer.
Paper Details　
Original Abstract of the Article :
Introduction C-reactive protein (CRP) is an acute-phase reactant used as a general marker for inflammation. Isolated levels have been associated with prostate cancer development, prostate-specific antigen (PSA), Gleason score, and treatment response. We seek to establish whether CRP levels reflect i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673689/

データ提供：米国国立医学図書館（NLM）

C-Reactive Protein: A Poor Marker for Prostate Cancer Inflammation

The field of oncology is constantly searching for reliable markers to guide cancer diagnosis and treatment. This study delves into the world of prostate cancer and explores the role of C-reactive protein (CRP), a marker for inflammation, in this disease. The researchers investigated the relationship between CRP levels and inflammation in patients with prostate cancer, analyzing CRP levels at different time points before, during, and after treatment. Their findings suggest that CRP is a poor marker of baseline inflammation in prostate cancer and response to treatment.

CRP is Not a Reliable Indicator of Prostate Cancer Inflammation

The study found that CRP levels did not consistently reflect inflammation caused by prostate cancer. This suggests that CRP may not be a reliable marker for monitoring inflammation in prostate cancer patients.

Understanding the Limitations of Biomarkers

This research highlights the importance of considering the limitations of biomarkers in clinical practice. CRP, while a valuable marker in certain contexts, may not be a reliable indicator of inflammation in prostate cancer.

Dr.Camel's Conclusion

Just as a camel needs to adapt to the changing sands of the desert, researchers are constantly seeking new ways to understand and manage cancer. This study sheds light on the limitations of CRP as a marker for prostate cancer inflammation, emphasizing the need for further research into more reliable biomarkers for this disease.

Date :
  1. Date Completed n.d.
  2. Date Revised 2021-12-21
Further Info :

Pubmed ID

34926085

DOI: Digital Object Identifier

PMC8673689

Related Literature

Article Analysis
・Effects of leuprolide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.